Article Sidebar
Views PDF: 109
EXTERNAL EVALUATION OF TACROLIMUS POPULATION PHARMACOKINETIC MODELS IN ADULT KIDNEY TRANSPLANT RECIPIENTS AT MILITARY HOSPITAL 103
Main Article Content
Abstract
Objectives: To screen and select an appropriate PopPK model in Vietnam kidney transplant recipients at Military Hospital 103. Methods: External evaluation was used to choose the proper model for our patients. The external dataset was obtained prospectively from 63 adult kidney transplant recipients treated at Military Hospital 103. All published tacrolimus PopPK models were systematically screened from PubMed and Scopus databases and were selected with covariate resemblance to our patient’s characteristics. Mean absolute prediction error (MAPE), mean prediction error (MPE), and goodness of fit plots were used to identify the appropriate model. Results: There were six models selected, among them, the model of Zhu et al. (2018) had a good predictive ability with MAPE = 29.89, MPE = -0.48. The GOF plot of this model also revealed similar results when the trend line between the predicted and observed tacrolimus concentrations was quite close to the standard curve (y = x). Conclusion: The Zhu’s model allowed good forecasting of tacrolimus trough concentrations in kidney transplant recipients at Military Hospital 103 and may support physicians in Tac dose adjustment along with clinical practice.
Article Details
Keywords
Kidney transplantation, Tacrolimus, Population pharmacokinetic model, External evaluation
References
2. Han N, Yun HY, Hong JY, Kim IW, Ji E, Hong SH, et al. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol. 2013; 69(1):53-63.
3. Zhang HJ, Li DY, Zhu HJ, Fang Y, Liu TS. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients. J Clin Pharm Ther. 2017; 42(4):425-32.
4. Han N, Ha S, Yun HY, Kim MG, Min SI, Ha J, et al. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin Pharmacol Toxicol. 2014; 114(5):400-6.
5. Woillard JB, de Winter BC, Kamar N, Marquet P, Rostaing L, Rousseau A. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations-twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol. 2011; 71(3):391-402.
6. Zhu W, Xue L, Peng H, Duan Z, Zheng X, Cao D, et al. Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients. 2018; 19(13): 1013-25.
7. Ling J, Dong LL, Yang XP, Qian Q, Jiang Y, Zou SL, et al. Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation. Xenobiotica. 2020; 50(12):1501-9.
8. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical pharmacogenetics implementation consortium (cpic) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015; 98(1):19-24.
9. Methaneethorn J, Lohitnavy M, Onlamai K, Leelakanok N. Predictive performance of published tacrolimus population pharmacokinetic models in thai kidney transplant patients. Eur J Drug Metab Pharmacokinet. 2022; 47(1):105-16.
10. Brunet M, van Gelder T, Asberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: Second Consensus Report. Ther Drug Monit. 2019; 41(3):261-307.